IN2014DN09990A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09990A
IN2014DN09990A IN9990DEN2014A IN2014DN09990A IN 2014DN09990 A IN2014DN09990 A IN 2014DN09990A IN 9990DEN2014 A IN9990DEN2014 A IN 9990DEN2014A IN 2014DN09990 A IN2014DN09990 A IN 2014DN09990A
Authority
IN
India
Prior art keywords
individual
pterostilbene
glucuronosyltransferase
ugt
udp
Prior art date
Application number
Inventor
Jeremy Bartos
Ryan Dellinger
Original Assignee
Chromadex Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc, Univ California filed Critical Chromadex Inc
Publication of IN2014DN09990A publication Critical patent/IN2014DN09990A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A method is provided for treating an individual for a cellular proliferative disorder , including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP -glucuronosyltransferase (UGT) activity is increased. In an embodiment , 12- HETE levels can be reduced by administration of pterostilbene.
IN9990DEN2014 2012-05-08 2012-11-14 IN2014DN09990A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/466,827 US8841350B2 (en) 2011-05-11 2012-05-08 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
PCT/US2012/064993 WO2013169291A2 (en) 2012-05-08 2012-11-14 Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Publications (1)

Publication Number Publication Date
IN2014DN09990A true IN2014DN09990A (en) 2015-08-14

Family

ID=47142275

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9990DEN2014 IN2014DN09990A (en) 2012-05-08 2012-11-14

Country Status (12)

Country Link
US (2) US8841350B2 (en)
EP (1) EP2846785A4 (en)
JP (1) JP2015523963A (en)
KR (1) KR20150027081A (en)
CN (1) CN104768543A (en)
AU (1) AU2012379655B2 (en)
BR (1) BR112014027646A2 (en)
CA (1) CA2872623A1 (en)
IN (1) IN2014DN09990A (en)
MX (1) MX2014013503A (en)
WO (1) WO2013169291A2 (en)
ZA (1) ZA201408893B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037007A1 (en) * 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
CA2959756C (en) * 2014-09-04 2023-02-28 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin
AU2016274126A1 (en) * 2015-06-10 2018-01-18 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
DE10161253A1 (en) 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Use of dihydropinosylvin and its derivatives as inhibitors
FR2869229B1 (en) 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli USE OF A INDUCER OF UGT BY TOPIC
ES2246165B1 (en) 2004-07-20 2006-12-01 Universitat De Valencia COMBINED USE OF PTEROSTILBENE AND QUERCETINE FOR THE MANUFACTURE OF USEFUL MEDICINES IN THE TREATMENT OF CANCER.
WO2008070872A1 (en) 2006-12-07 2008-06-12 Rutgers, The State University Of New Jersey Prevention and treatment of colon cancer
US8509879B2 (en) 2007-11-06 2013-08-13 The Regents Of The University Of California Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging
EP2231133A4 (en) * 2008-01-08 2014-08-20 David Rubin Method and compositions for administering resveratrol and pterostilbene
US20090324740A1 (en) 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
US20100240767A1 (en) 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
US9737495B2 (en) 2009-06-22 2017-08-22 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
US20110136751A1 (en) 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
EP2322159A1 (en) 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US8513236B2 (en) * 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
EP2673250B1 (en) 2011-01-28 2016-11-23 University of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
JP6155191B2 (en) * 2011-10-02 2017-06-28 キユーピー株式会社 Accelerator for promoting suppression of mRNA expression by RNA interference and use thereof

Also Published As

Publication number Publication date
US8841350B2 (en) 2014-09-23
WO2013169291A2 (en) 2013-11-14
MX2014013503A (en) 2015-11-13
CA2872623A1 (en) 2013-11-14
CN104768543A (en) 2015-07-08
JP2015523963A (en) 2015-08-20
BR112014027646A2 (en) 2017-06-27
AU2012379655A1 (en) 2014-11-20
WO2013169291A3 (en) 2015-06-18
AU2012379655B2 (en) 2018-01-18
US10039725B2 (en) 2018-08-07
EP2846785A2 (en) 2015-03-18
US20120289605A1 (en) 2012-11-15
EP2846785A4 (en) 2016-06-15
KR20150027081A (en) 2015-03-11
ZA201408893B (en) 2016-08-31
US20150011650A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
PH12015502075B1 (en) Treatment of cataplexy
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12018502731A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
BR112012033738A2 (en) Method for treating bipolar disorder
MX350666B (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia.
MX2013012785A (en) Multiple myeloma treatment.
MX2015014590A (en) Treatment of cancer with dihydropyrazino-pyrazines.
MX361458B (en) Pyrimido- pyridazinone compounds and use thereof.
IN2014DN09990A (en)
MX2016002308A (en) Multiple myeloma treatment.
MX2014006990A (en) Treatment of type i and type ii diabetes.
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
UA82641U (en) Method for treating neurosyphilis with parenchymatous alterations
UA58066U (en) Method for treating genital viral infection
UA46514U (en) Method for topical treatment of limited scleroderma